Braun, F., Abed, A., Sellung, D., Rogg, M., Woidy, M., Eikrem, O., Wanner, N., Gambardella, J., Laufer, S. D., Haas, F.
, Wong, M. N., Dumoulin, B., Rischke, P., Mühlig, A., Sachs, W., von Cossel, K., Schulz, K., Muschol, N., Gersting, S. W. ... Huber, T. B. (2023).
Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
The Journal of clinical investigation,
133(11), Article e157782.
https://doi.org/10.1172/JCI157782Thein, D., Rosenø, N. A. L., Maul, J.-T., Wu, J. J., Skov, L., Bryld, L. E.
, Rasmussen, M. K., Ajgeiy, K. K., Thomsen, S. F., Thyssen, J. P. & Egeberg, A. (2023).
Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment: a nationwide cohort study.
The Journal of Investigative Dermatology,
143(11), 2211-2218.e4.
https://doi.org/10.1016/j.jid.2023.04.009Flohr, C., Irvine, A. D., Cork, M. J., Simpson, E. L., Wollenberg, A.
, Deleuran, M., Praestgaard, A., Thomas, R. B. & Rossi, A. B. (2023).
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
British Journal of Dermatology,
189(2), 238-240.
https://doi.org/10.1093/bjd/ljad124